Wedbush analyst Liana Moussatos reiterated a Buy rating on ObsEva SA (OBSV) today and set a price target of $34. The company’s shares opened today at $14.94.
According to TipRanks.com, Moussatos has currently no stars on a ranking scale of 0-5 stars, with an average return of -10.4% and a 33.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Aquestive Therapeutics Inc, Allena Pharmaceuticals Inc, and Global Blood Therapeutics.
Currently, the analyst consensus on ObsEva SA is a Strong Buy with an average price target of $33.25, representing a 122.6% upside. In a report released yesterday, H.C. Wainwright also reiterated a Buy rating on the stock with a $44 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $20.35 and a one-year low of $9.05. Currently, ObsEva SA has an average volume of 108K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ObsEva SA engages in the development of therapeutic treatments for woman’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet in November 2012 and is headquartered in Geneva, Switzerland.
